Please assess the completion status of the following clinical trial:

Trial Title: Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women ≥40 years-old~* Early postmenopausal, defined as:~* No menstrual bleeding for 12-60 months secondary to natural menopause, according to STRAW criteria48~* Hysterectomy without bilateral oophorectomy if surgery was completed after 6+ months of amenorrhea (no maximum duration of amenorrhea required)~* Bilateral oophorectomy (no minimum or maximum duration of amenorrhea required)~* Serum follicle-stimulating hormone (FSH) \>25 IU/L and estradiol \<20 pg/ml~* Diagnosis of major depression on the MINI~* Mild-to-moderate depressive symptoms, as indicated by MADRS score 15-31 and BDI score \>15~* Normal mammogram within the past 2 years~* Good general health~Exclusion Criteria:~* Severe depression, defined as a MADRS score \>31, psychotic symptoms, or suicidal or homicidal ideation~* Psychiatric illness, as defined by clinical interview and the Mini-International Neuropsychiatric Interview (MINI), as:~  * A lifetime history of bipolar disorder~ * A lifetime history of severe depression, as characterized by current or prior psychotic symptoms, inpatient psychiatric hospitalization or a suicide attempt in the previous 5 years, or~ * Current panic disorder or obsessive compulsive disorder~ * A lifetime history of psychotic symptoms~ * Current anorexia nervosa~ * An alcohol or substance-use disorder active within the past year~ * Current suicidal or homicidal ideation~* Previous diagnosis of a sleep disorder (sleep apnea, PLMS, etc) or diagnosed on a screening PSG study~* Pregnant, confirmed with serum ß-HCG at baseline (Visit 1)~* Breastfeeding~* Contraindication, hypersensitivity, or previous adverse reaction to E2 therapy~* Current or recent (1 month) use of centrally active medications (antidepressants, anxiolytics, hypnotics, anticonvulsants, stimulants)~* Current or recent (2 months) use of systemic hormone medications~* History of breast cancer, premalignant breast lesions, or undiagnosed breast mass~* Vaginal spotting or bleeding~* History of thrombo-embolism, cardiovascular disease, congestive heart failure or other contraindication to estradiol therapy.~* Liver dysfunction or disease~* Renal insufficiency~* Contraindications to progestin therapy~* Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable and under medical management~* Other medical contraindications to estradiol and progestin therapy including porphyria, systemic lupus erythematosus, hepatic hemangiomas, deep vein thrombosis, hereditary angioedema, hypertriglyceridemia, severe Hypocalcemia.~* Clinically significant abnormalities in screening blood tests including:~  * Thyroid-stimulating hormone \<0.50 or \>5.0 uU/mL)~ * Shift workers

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Estradiol (Type: EXPERIMENTAL): None
- Placebo control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).